Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge

Abstract

Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults.